

# Prescribing Indicators 2017/18 in general practice

The NHS Lothian Prescribing Indicators (PIs) for 2017/18 have been agreed by the General Practice Prescribing Committee (GPPC) and are listed below. The main points to note are:-

- 3 indicators have a revised target: co-amoxiclav, fluoroquinolones and esomeprazole
- 6 measures are unchanged: generics, total antibiotics, PPIs, high strength inhaled corticosteroids and hypnotics & anxiolytics
- 1 new measure: gabapentinoids (pregabalin and gabapentin)
- 7 of 10 measures directly support National Therapeutic Indicators developed by the Scottish Government Therapeutics Branch
- The 3 antibiotic PIs are measured over a 12-month period, all the other PIs are measured over a 3-month period
- Total of 10 PIs for 2017/18

1. **GENERIC PRESCRIBING (unchanged)**  
Overall generic rate (**excluding contraceptives**)  $\geq 80.00\%$
2. **TOTAL ANTIBIOTICS (unchanged)**  
Items per 1000 patients per day  $\leq 1.90$
3. **CO-AMOXICLAV (REVISED TARGET)**  
Items per 1000 patients per day  $\leq 0.075$
4. **FLUOROQUINOLONES (REVISED TARGET)**  
Items per 1000 patients per day  $\leq 0.055$
5. **ESOMEPRAZOLE (REVISED TARGET)**  
Total number of items of esomeprazole 20mg  $\leq 1.50\%$  of esomeprazole and LJJ recommended PPIs (**excluding esomeprazole granules**)
6. **PROTON PUMP INHIBITORS (PPIs) (unchanged)**  
PPIs DDDs\* per 1000 patients per day  $\leq 105.00$  or a 5% reduction against practice Q3 baseline measure (Dec 2016) (2 tier)
7. **ROSUVASTATIN (unchanged)**  
Rosuvastatin 5mg and 10mg DDDs\*  $\leq 1.50\%$  of all statins
8. **HIGH STRENGTH INHALED CORTICOSTEROIDS (unchanged)**  
Total number of items of high strength inhaled corticosteroids (**excluding Fostair<sup>®</sup>**)  $\leq 38.00\%$  of all corticosteroid inhalers (items) or a 10% reduction from baseline Q4 (Dec 2016) (2 tier)
9. **HYPNOTICS AND ANXIOLYTICS (unchanged)**  
Hypnotics and anxiolytics DDDs\* per 1000 patients per day  $\leq 20.00\%$  or a 10% reduction from baseline Q4 (Dec 2016) (2 tier)
10. **GABAPENTINOIDS (new measure - to support review of use in chronic pain only)**  
Pregabalin and gabapentin DDDs\* per 1,000 patients per day  $\leq 14.00$  or a 5% reduction from baseline Q3 (Dec 2016) (2 tier)

\*DDDs = 'defined daily doses: average maintenance daily dose of the drug for its main indication in adults'